Ubenimex Market Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The global ubenimex market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Ubenimex, also known as bestatin, is a competitive, reversible protease inhibitor and It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N, it is for use in the treatment of acute myelocytic leukemia. The increasing prevalence of chronic disease among geriatric population has created a demand for the development of new tablets for its treatment which in turn drives the global ubenimex market growth.

The major healthcare companies are focusing on the development of ubenimex for the treatment of acute myelocytic leukemia. Therefore, the market growth is driven by the strong focus of the healthcare companies and research organizations on the R&D of drugs for ubenimex tablet creating a strong pipeline for effective use. The increasing cases of acute myeloid leukemia can be attributed to a number of factors such as poor health, genetic modification, radiation exposure, and increased exposure to toxic chemicals such as benzene. According to American research in 2019, there were approximately 61,780 new cases of leukemia and 22,840 mortalities in the US, and the number of cases of acute myeloid leukemia is estimated at 21,450, with adults making up the majority of patients.

The growing prevalence and high mortality rate in the US and other countries pave the way for the higher adoption of complementary therapies that increased the market growth in the ubenimex market. In December 2018, Eli Lilly & Co. and AC Immune collaborated to develop a new treatment for chronic disease using AC acute myelocytic leukemia platform, and this collaboration is expected to promote the growth of the global ubenimex market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- AbbVie Inc., Abcam plc., APExBIO Technology LLC, BioVision,Inc., Enzo Biochem Inc., and Takeda Pharmaceutical Co. Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Ubenimex Market Report by Segment

By Type

• Tablets
• Capsules

By Application

• Treatment of Acute Myelocytic Leukemia
• Others